Literature DB >> 32100878

Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.

Yasutaka Aoki1,2, Masamichi Mizuma1, Tatsuo Hata1, Takeshi Aoki1, Yuko Omori2, Yusuke Ono3, Yusuke Mizukami3,4, Michiaki Unno1, Toru Furukawa2.   

Abstract

Intraductal papillary neoplasm of the bile duct (IPNB) is a grossly visible papillary biliary neoplasm with morphological variations and occasional invasion. Recently a new classification of IPNB into type 1 and type 2 was proposed in which the type 1 IPNBs consist of fine papillary neoplastic glands and the type 2 IPNBs consist of complex branching glands, seldom with foci of solid-tubular components. However, clinicopathological and molecular characteristics of these types of IPNBs are yet to be identified. We aimed to uncover clinicopathological and molecular characteristics of the types of IPNBs. Thirty-six IPNBs were studied retrospectively. Clinicopathological features as well as molecular alterations of 31 genes were evaluated by means of targeted next-generation sequencing and immunohistochemical examination of expression of mucin and cancer-associated molecules. The 36 IPNBs were classified into 22 of type 1 and 14 of type 2. The type 1 IPNBs were associated with a non-invasive phenotype, intestinal and oncocytic subtypes, development in the intrahepatic bile duct, overt mucin production, and a relatively good prognosis. The type 2 IPNBs were associated with an invasive phenotype, the pancreatobiliary subtype, development within the extrahepatic bile duct, and worse prognosis compared with the type 1 IPNBs. In the molecular analysis, recurrent mutations were found in TP53 (34.3%), KRAS (31.4%), STK11 (25.7%), CTNNB1 (17.1%), APC (14.3%), SMAD4 (14.3%), GNAS (11.4%), PBRM1 (11.4%), ELF3 (8.6%), KMT2C (8.6%), NF1 (8.6%), PIK3CA (8.6%), ARID1A (5.7%), ARID2 (5.7%), BAP1 (5.7%), BRAF (5.7%), EPHA6 (5.7%), ERBB2 (5.7%), ERBB3 (5.7%), KMT2D (5.7%), and RNF43 (5.7%). Mutations in KRAS and GNAS were enriched in the type 1 IPNBs, whereas mutations in TP53, SMAD4, and KMT2C were enriched in the type 2 IPNBs. These results indicate that IPNBs consist of two distinct types of neoplasms specifically associated with clinicopathological features and molecular phenotypes.
© 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  biliary cancer; cholangiocarcinoma; genetics; molecular subtyping; prognosis; targeted sequencing

Year:  2020        PMID: 32100878     DOI: 10.1002/path.5398

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience.

Authors:  Amira Salah El-Din Youssef; Mohamed A Abdel-Fattah; Mai M Lotfy; Auhood Nassar; Mohamed Abouelhoda; Ahmed O Touny; Zeinab K Hassan; Mohammed Mohey Eldin; Abeer A Bahnassy; Hussein Khaled; Abdel Rahman N Zekri
Journal:  Curr Issues Mol Biol       Date:  2022-03-18       Impact factor: 2.976

Review 2.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

Review 3.  Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.

Authors:  Taek Chung; Young Nyun Park
Journal:  Front Med (Lausanne)       Date:  2022-03-31

4.  Comparison of the Malignant Predictors in Intrahepatic and Extrahepatic Intraductal Papillary Neoplasm of the Bile Duct.

Authors:  Sung Yong Han; Dong Uk Kim; Hyeong Seok Nam; Dae Hwan Kang; Sung Ill Jang; Dong Ki Lee; Dong Woo Shin; Kwang Bum Cho; Min Jae Yang; Jae Chul Hwang; Jin Hong Kim; Hoonsub So; Sung Jo Bang; Min Je Sung; Chang-Il Kwon; Dong Wook Lee; Chang-Min Cho; Jae Hee Cho
Journal:  J Clin Med       Date:  2022-04-02       Impact factor: 4.241

5.  Whole-exome sequencing for a more accurate diagnosis of intraductal papillary neoplasms of the bile duct.

Authors:  Tomoaki Matsumori; Norimitsu Uza; Nobuyuki Kakiuchi; Toshihiro Morita; Yoshihiro Nishikawa; Masahiro Shiokawa; Kojiro Taura; Yuzo Kodama; Hiroshi Seno
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-04-10

6.  Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.

Authors:  Benjamin Goeppert; Damian Stichel; Reka Toth; Sarah Fritzsche; Moritz Anton Loeffler; Anna Melissa Schlitter; Olaf Neumann; Yassen Assenov; Monika Nadja Vogel; Arianeb Mehrabi; Katrin Hoffmann; Bruno Köhler; Christoph Springfeld; Dieter Weichenhan; Christoph Plass; Irene Esposito; Peter Schirmacher; Andreas von Deimling; Stephanie Roessler
Journal:  Gut       Date:  2021-01-19       Impact factor: 23.059

Review 7.  Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review.

Authors:  Mukul Vij; Yogesh Puri; Ashwin Rammohan; Gowripriya G; Rajesh Rajalingam; Ilankumaran Kaliamoorthy; Mohamed Rela
Journal:  World J Gastrointest Oncol       Date:  2022-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.